Aktienanalyse zu Abbott Laboratories (ABT)ABTAbbott Laboratories

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abbott Laboratories is a good buy right now due to its current price of $99.60, which is significantly below the analyst price targets ranging from $120 to $127. The forward P/E ratio is 17.094, indicating potential for growth compared to its current valuation. Additionally, the recent product launch of Ensure Max Protein is expected to drive revenue growth, while the RSI of 50.277 suggests the stock is neither overbought nor oversold, making it a favorable entry point.

20 analysts cover ABT: 13 rate it Buy, 7 Hold and 0 Sell. The average price target is 148.11.